All times shown are PDT (GMT-7) (San Francisco)
Displaying One Session
Abstract Sessions On-Demand Channel
Oral abstract session
Room
Abstract Sessions On-Demand Channel
Oral abstract session
Introduction
Session Name
Room
Abstract Sessions On-Demand Channel
Oral abstract session
Dolutegravir- versus low-dose Efavirenz-based regimen for the initial treatment of HIV-1 infection in Cameroon: Week 96 results of the ANRS 12313 – NAMSAL trial
Session Name
Room
Abstract Sessions On-Demand Channel
Oral abstract session
Pooled analysis of 4 international trials of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older demonstrating safety and efficacy: Week 48 results
Speaker
Session Name
Room
Abstract Sessions On-Demand Channel
Oral abstract session
Third-line antiretroviral therapy including raltegravir, darunavir/ritonavir and/or etravirine is well tolerated and achieves durable virologic suppression over 144+ weeks in resource limited settings ACTG: A5288 strategy trial
Session Name
Room
Abstract Sessions On-Demand Channel
Oral abstract session
Sub-optimal outcomes with switching to zidovudine vs. recycling tenofovir in second-line treatment in Haiti
Speaker
Session Name
Room
Abstract Sessions On-Demand Channel
Oral abstract session
Conclusion
Session Name
Room
Abstract Sessions On-Demand Channel